Arthneeti
All Q1 FY27 results →
G

India Glycols Ltd

Q1 FY27Beverages

India Glycols Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,190
Market cap₹7.7K Cr
P/E24.2
Updated26 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

Future growth expectations for India Glycols Limited (IGL) in sales/revenue/volumes include: - Potable Spirits segment expects revenue growth to exceed volume growth due to premiumization and new high-margin offerings in deluxe whisky, semi-premium vodka, and white spirits. India Glycols aims for an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already delivered in Q1.

From India Glycols Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Moderate growth
Future growth expectations for India Glycols Limited (IGL) in sales/revenue/volumes include: - Potable Spirits segment expects revenue growth to exceed volume growth due to premiumization and new high-margin offerings in deluxe whisky, semi-premium vodka, and white spirits. - IMFL revenue expected to be over 30% of Potable Spirit revenue in FY27. - Doubling of potable spirits volume planned for FY27 with deeper state penetration and new brand launches. - Spirits business targeting EBITDA over INR 500 crores in FY27, aiming for INR 1,000 crores in 4-5 years. - Chemicals business shows 25% YoY revenue growth; pipeline strong in performance chemicals. - ENNature Bio Pharma targeting INR 130-150 crores EBITDA over next 4-5 years with growth in nicotine and nutraceuticals.

2 more points from India Glycols Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what India Glycols Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • For the NSU (Nutraceuticals and Specialty Uses) segment, incremental capex of approximately INR 5-20 crores is planned for the current year.
  • No major large-scale capex (like INR 400-500 crores plant) is expected in the next 2 years unless new technologies are pursued.
  • Modular expansion approach will be followed as business grows.
  • The core plant expansion till now involved around INR 50-60 crores investment, utilizing some existing assets.
  • Investment plans include scaling up capacity, new product introductions, and customer engagement to grow NSU business.

2 more points from India Glycols Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Beverages

Ranked on what management guided this quarter

Guidance-ranked
1Piccadily Agro
Rev 1Mar 3
2Varun Beverages
Rev 2Mar 3
3
Rev 2Mar 3
4
Rev 3Mar 1
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what India Glycols Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant points related to business outlook and growth include: - Ennature Bio Pharma has a strong order pipeline supporting 26% growth in Thiocolchicoside sales. - The Spirits business is targeting healthy double-digit volume growth driven by new offerings and deeper penetration.

2 more points from India Glycols Ltd's call on order book

Create a free account to keep reading this call

India Glycols Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹976 Cr, net profit ₹87 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What India Glycols's management said in earlier quarters

Others in Beverages this season

  • Suraj Industries (Q1 FY27)

    Revenue from operations for Q1FY27: Rs 73 Cr (Page 24) . Key investor presentation takeaways from Suraj Industries Ltd's Q1 FY27 investor presentation — and how

  • United Spirits (Q1 FY27)

    Marketing spends are steady at **10.5%-11% of net sales** to support brand investments and growth. Key concall takeaways from United Spirits Ltd's Q1 FY27…

  • Piccadily Agro (Q1 FY27)

    Whistler brand shows double-digit to higher double-digit growth, having grown almost 100% year-on-year in the last year. Key concall takeaways from Piccadily…

  • FratelliVineyard (Q1 FY27)

    The industry, particularly RTD, is growing at approximately 25% annually. Key concall takeaways from Fratelli Vineyards Ltd's Q1 FY27 earnings call — and how…

Compare:vs Varun Beveragesvs United Spiritsvs Radico Khaitan Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

India Glycols Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were India Glycols Ltd Q1 FY27 results?

Future growth expectations for India Glycols Limited (IGL) in sales/revenue/volumes include: - Potable Spirits segment expects revenue growth to exceed volume growth due to premiumization and new high-margin offerings in deluxe whisky, semi-premium vodka, and white spirits. India Glycols aims for an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already delivered in Q1.

What is India Glycols Ltd share price analysis?

India Glycols Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.2 with a market cap of ₹7,685 Cr. Investors should review the full earnings analysis for detailed insights.

Is India Glycols Ltd planning capital expenditure?

For the NSU (Nutraceuticals and Specialty Uses) segment, incremental capex of approximately INR 5-20 crores is planned for the current year.

Keep India Glycols Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.